PBPinki Biswas

Pinki Biswas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pinki Biswas has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Optimization and Characterization of Chlorthalidone Bilayer Tablets for Chronotherapeutic Pulsatile Drug Release

    by Moulindu Mondal, Deepannita Roy Mukherjee, Dona Biswas, Pinki Biswas, Saikat Santra

    Pulsatile Drug Delivery System (PDDS) is defined as the rapid and transient release of drug molecules within a short time period immediately after a predetermined lag (off release) period. Blood pressure exhibits a well-documented circadian surge in the early morning hours — a window associated with peak cardiovascular morbidity. Chlorthalidone, a BCS Type-II thiazide-like diuretic with a plasma half-life of 40–60 hours, was selected as the model drug for a chronopharmacological pulsatile formulation. Nine bilayer press-coated tablet formulations (CHT-A through CHT-I) were prepared using Hydroxypropyl Methylcellulose K100M (HPMC) as the hydrophilic swelling polymer and Ethyl Cellulose (EC) as the hydrophobic rupturable membrane at varying weight ratios. Preformulation studies — including ATR-IR spectroscopy, Differential Scanning Calorimetry (DSC), and powder flow characterization — confirmed drug identity, thermal behaviour, and excipient compatibility. Scanning Electron Microscopy (SEM) was employed to characterize surface morphology. The core tablet exhibited a disintegration time of 185 seconds and 95.8% drug content. Formulation CHT-G (HPMC 150 mg: EC 250 mg) demonstrated the optimal 6-hour lag time followed by a burst release of 83.20% at hour 7. Korsmeyer-Peppas modelling (R² = 0.8545; n = 2.2082) identified super case-II swelling-controlled transport as the dominant release mechanism. The developed system offers a clinically promising chronopharmacological strategy for the management of morning-surge hypertension. Keywords: Pulsatile Drug Delivery; Chlorthalidone; Bilayer Tablet; HPMC; Ethyl Cellulose; DSC; SEM; Lag Time; Chronopharmacology; Hypertension

  • Open Access

    Isolation and characterization of flavonoid fractions from orange peel with antioxidant properties

    by Saikat Santra, Pinki Biswas, Soumyadeb Dutta, Deepannita R. Mukherjee

    Background: Citrus sinensis peel is an abundant agro-industrial byproduct rich in flavonoids and a potentially underexploited source of natural antioxidants. This study aimed to extract, characterize, and evaluate the antioxidant potential of flavonoid fractions from orange peel for food and pharmaceutical applications. Methods: Dried Citrus sinensis peel underwent hydroalcoholic extraction (ethanol: water, 1:1 v/v) for 72 hours by column chromatography purification. Characterization utilized HPLC, UV-Vis, and FTIR spectroscopy. Antioxidant activity was quantified via DPPH radical scavenging and FRAP assays. Results: HPLC identified hesperidin as the predominant flavonoid (52.4 mg/g extract), followed by naringin (18.9 mg/g), rutin (13.7 mg/g), and quercetin (8.5 mg/g). Total flavonoid content was 4.29 mg quercetin equivalents/g extract. The extract demonstrated concentration-dependent DPPH scavenging (32.4–88.6% at 0.5–2.5 mg/ml; IC₅₀=1.21 mg/ml) and strong ferric reducing capacity (1655±18 µmol Fe(II)/g). FTIR confirmed characteristic flavonoid functional groups. Conclusions: Citrus sinensis peel extract exhibits significant antioxidant activity, validating its potential as a sustainable natural antioxidant source for food preservation and pharmaceutical formulations.


  • Open Access

    Chrono-Colonic Delivery in Engineering Time-Responsive Systems for Site-Specific Therapy

    by Raktim Sarkar, Pinki Biswas, Deepannita Roy Mukherjee, Sayak Tanbir, Bimaneshwar Biswas, Mostafijur Rahaman, Saikat Santra

    Background: Chrono-colonic drug delivery represents a novel pharmaceutical engineering strategy that combines the principles of circadian rhythm-based chronotherapy with colon-targeted the drug delivery. This approach seeks to optimize therapeutic efficacy by synchronizing drug release with the body’s biological clock while ensuring precise site-specific delivery. Objective: The primary aim of chrono-colonic delivery is to achieve controlled drug release after a predetermined lag time, ensuring that the therapeutic effect coincides with peak disease activity and that the drug reaches the colon for localized or systemic action. Methods: This strategy integrates time-dependent and site-specific technologies, employing pH-sensitive polymers, biodegradable coatings, osmotic systems, and microbially triggered release platforms. These delivery systems are designed to withstand the upper gastrointestinal tract environment and to release the active agent in the colon, where favorable physiological conditions such as near-neutral pH, slower motility, and microbial activity can be exploited. Results: Chrono-colonic delivery systems offer significant therapeutic benefits, including improved precision of drug action, reduced systemic side effects, and enhanced patient compliance. They are particularly beneficial in managing diseases with circadian variability, such as asthma, hypertension, arthritis, ulcerative colitis, and inflammatory bowel disease. Conclusion: By integrating chrono-therapeutic principles with colon-targeted technologies, chrono-colonic drug delivery holds promise as a next-generation approach for achieving site- and time-specific therapy. It represents a forward-looking strategy for addressing both local and systemic diseases with enhanced safety and efficacy. Keywords: Chrono-Colonic Delivery, Circadian Rhythm, Colon-Targeted Drug Delivery, Time-Responsive Systems, Site-Specific Therapy, Chronotherapy


  • Open Access

    Exploring the Gut Microbiome's Influence on Peptic Ulcer Disease: Mechanistic Insights, Pharmacological Implications, and Emerging Therapeutic Strategies

    by Deepannita Roy Mukherjee, Sayak Tanbir, Sohel Mondal, Soumik Tarafder, Dona Biswas, Soumyadeb Dutta, Saikat Santra, Pinki Biswas

    Background: The gastrointestinal disorder Peptic Ulcer Disease (PUD) leads to mucosal damage in either stomach or duodenal tissue because of acid-peptic injury. The available evidence demonstrates that Helicobacter pylori (H. pylori) infection and nonsteroidal anti-inflammatory drug (NSAID) usage serve as proven ulcer causes but new research shows the gut microbiome as contributing to ulcer development and therapeutic approaches. Objective: The purpose of this section is to examine the standard H. pylori ulcer development process while examining host immune responses through gut microbial alterations and their effect on PUD disease progression. Methods: This study reviewed multiple research articles to examine how bacteria affect epithelial cells while studying inflammatory pathways as well as microbial metabolites particularly short-chain fatty acids (SCFAs). The review examined different pharmacy-based and natural therapies from the perspective of their ability to modulate the microbiome. Results: The research shows Non-H. Pylori bacteria damage gastric mucosal tissue by activating pro-inflammatory cytokines which leads to gastric homeostasis disturbances because of SCFA production. The ulcer formation gets worse because dysbiosis makes the intestines more sensitive to oxidative stress while simultaneously making the protective mucosal layer weaker. Antibiotics together with proton pump inhibitors affect gut microbial composition but natural treatments including curcumin combined with ginger and probiotics both contribute to microbial recovery and healing of ulcers. Conclusion: Previous research about the gut microbiome's role in PUD pathogenesis forms a base for future development of tailored therapeutic strategies. Combining microbiome-based therapeutic methods with traditional medical protocols produces better management strategies for ulcers with improved healthcare results for patients. Keywords:Peptic Ulcer Disease, Gut Microbiota, Microbial Dysbiosis, Immunoglobulin A (IgA), Gastrointestinal Inflammation, Mucosal Homeostasis